The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.. 2014.
Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.. 2014.
HIV Virulence has not increased in the UK subtype B epidemic. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.. 2014.
Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan. J Virol. 88:9864-76.. 2014.
National audit of baseline HIV resistance testing among newly-diagnosed adults. Third Joint Conference of BHIVA and BASHH, 1-14 April 2014.. 2014.
Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One. 9:e83337.. 2014.
Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS. 28:1967-75.. 2014.
Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.. 2014.
Sustained Spread of HIV-1 Drug Resistance in Treatment-Naïve Patients in the United Kingdom. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.. 2014.
Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.. 2013.
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.. 2013.
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.. 2013.
Dynamics of Non-B HIV Transmission in the UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.. 2013.
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.. 2013.
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.. 2013.
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.. 2013.
Non-B HIV transmission networks in the UK. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.. 2013.